Cytokinetics, Incorporated (CYTK)
$
40.19
-3.00 (-7.46%)
Key metrics
Financial statements
Free cash flow per share
-3.5703
Market cap
5.4 Billion
Price to sales ratio
291.1882
Debt to equity
-5.8260
Current ratio
6.1664
Income quality
0.6715
Average inventory
0
ROE
5.3974
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The cost of revenue for the company is $0.00 showcasing its production and operational expenses. With a gross profit ratio of 1.00 the company reflects the efficiency of its production and sales operations. In terms of profitability, the company reported an income before tax of -$589,526,000.00 which highlights its pre-tax profitability. The total costs and expenses for the company amount to $554,722,000.00 reflecting its overall spending. Additionally, the EBITDA ratio is -26.71 underscoring the company's operational efficiency. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility, including omecamtiv mecarbil, a novel cardiac myosin activator currently in Phase III clinical trials for heart failure, as well as reldesemtiv, a skeletal muscle troponin activator undergoing Phase III trials for amyotrophic lateral sclerosis and spinal muscular atrophy. Other developments include CK-136, a cardiac troponin activator in Phase I trials, aficamten, a cardiac myosin inhibitor in Phase III trials for symptomatic obstructive hypertrophic cardiomyopathy, and CK-3772271, a small molecule cardiac myosin inhibitor currently in Phase I trials. The company, incorporated in 1997 and headquartered in South San Francisco, California, has a strategic alliance with Astellas Pharma Inc. The stock is affordable at $41.79 making it suitable for budget-conscious investors. Moreover, the stock has a high average trading volume of 1,626,483.00 which indicates strong liquidity. With a mid-range market capitalization of $4,758,938,090.00 the company is considered a steady performer. As a key player in the Biotechnology industry, Cytokinetics contributes significantly to the overall market landscape, while it belongs to the Healthcare sector, driving innovation and growth. This combination of financial stability and progressive R&D positions Cytokinetics as an attractive consideration for potential investors aiming for meaningful engagement in the biopharmaceutical field.
What is Cytokinetics, Incorporated (CYTK)'s stock forecast?
Analysts predict Cytokinetics, Incorporated stock to fluctuate between $39.81 (low) and $75.71 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Cytokinetics, Incorporated's market capitalization?
As of 2025-04-01, Cytokinetics, Incorporated's market cap is $4,758,938,090, based on 118,411,000 outstanding shares.
How does Cytokinetics, Incorporated compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Cytokinetics, Incorporated has a Lower Market-Cap, indicating a difference in performance.
How can I buy Cytokinetics, Incorporated (CYTK) stock?
To buy Cytokinetics, Incorporated (CYTK) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CYTK. Place an order (Market, Limit, etc.).
What is the best time to invest in Cytokinetics, Incorporated?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Cytokinetics, Incorporated perform in the last earnings report?
Revenue: $18,474,000 | EPS: -$5.26 | Growth: -3.49%.
Where can I find Cytokinetics, Incorporated's investor relations reports?
Visit https://www.cytokinetics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Cytokinetics, Incorporated?
You can explore historical data from here
What is the all-time high and low for Cytokinetics, Incorporated stock?
All-time high: $110.25 (2024-01-08) | All-time low: $17.72 (2021-07-14).
What are the key trends affecting Cytokinetics, Incorporated stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
globenewswire.com
Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to Care SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the launch of EARTH-HCM (Epidemiology, Awareness, Real-world Treatment and Health Outcomes in HCM), an online, open access, interactive public health education tool developed by Cytokinetics in collaboration with leading academic institutions, that leverages real-world, de-identified claims data to visualize and analyze population differences in patient characteristics, treatments, clinical outcomes, healthcare resource utilization and costs in hypertrophic cardiomyopathy (HCM) in the U.S. EARTH-HCM is an innovative, user-friendly, interactive tool designed to bridge the gap in awareness and education about HCM by providing insights into the treatment landscape and disparities in care.
seekingalpha.com
Cytokinetics is now rapidly moving into commercialization efforts with Aficamten. If all goes well, it could be approved by September 2025. Aficamten had favorable Phase 3 data, so it could have solid competitive prospects if approved, possibly with better safety and simpler dosing. Although CYTK looks a bit pricey today, Aficamten's $10 billion TAM by 2035 makes CYTK's valuation much more reasonable.
zacks.com
CYTK reports a wider-than-expected Q4 loss as operating expenses increase. CYTK is gearing up to launch lead candidate aficamten upon a potential FDA approval.
seekingalpha.com
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Diane Weiser - Senior Vice President, Corporate Affairs Robert Blum - President & Chief Executive Officer Andrew Callos - Executive Vice President & Chief Commercial Officer Fady Malik - Executive Vice President, R&D Isaac Ciechanover - EVP Corporate Development and Chief Business Officer Stuart Kupfer - Senior Vice President & Chief Medical Officer Sung Lee - Executive Vice President & Chief Financial Officer Conference Call Participants Paul Choi - Goldman Sachs Cory Kasimov - Evercore ISI Salim Syed - Mizuho James Condulis - Stifel Tess Romero – JPMorgan Leonid Timashev - RBC Capital Markets Akash Tewari - Jefferies David Lebowitz - Citi Sean McCutcheon - Raymond James Srikripa Devarakonda - Truist Securities Roanoke Ruiz - Leerink Partners Joe Pantginis - H. C. Wainwright Mayank Mamtani - B.
zacks.com
Cytokinetics (CYTK) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.38 per share a year ago.
See all news
